NCELL® TECHNOLOGY:
Ocular tissue distribution of cyclosporine was evaluated in a total of 26 female New Zealand White rabbits that received a single dose (administered to both eyes) of vehicle, cyclosporine 0.05% or 0.1% with NCELL Technology, or a commercially available cyclosporine 0.05% emulsion (Restasis®, Allergan). Pharmacokinetic parameters for cyclosporine exposure were assessed in tears, whole blood, and ocular tissues.1,2
Delivering cyclosporine to ocular tissues, NCELL Technology encapsulates the cyclosporine, allowing it to penetrate the aqueous layer of the tear film.1,2
NCELL is engineered to address cyclosporine solubility challenges to better reach the ocular surface.1,3 By using a protective hydrophilic shell, NCELL Technology delivers encapsulated cyclosporine in a secured hydrophobic core to the ocular surface.1,3-5
This protective hydrophilic shell allows for transport through the tear film onto the ocular surface.1,3,4
This secured hydrophobic core prevents the encapsulated cyclosporine from being released until after penetrating the aqueous layer of the tear film.1,3-5
Designed to protect cyclosporine during its delivery to the ocular surface.1,3,4
NCELL provided superior delivery over emulsion
CEQUA® (cyclosporine ophthalmic solution) 0.09% is a calcineurin inhibitor immunosuppressant indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).
WARNINGS AND PRECAUTIONS
Potential for Eye Injury and Contamination: To avoid the potential for eye injury and contamination, advise patients not to touch the vial tip to the eye or other surfaces.
Use with Contact Lenses: CEQUA should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of CEQUA ophthalmic solution.
The most common adverse reactions reported in greater than 5% of patients were pain on instillation of drops (22%) and conjunctival hyperemia (6%). Other adverse reactions reported in 1% to 5% of patients were blepharitis, eye irritation, headache, and urinary tract infection.
Please see the Full Prescribing Information.
References: 1. US Patent 9,937,225 B2. 2. Data on file. Cranbury, NJ: Sun Pharmaceutical Industries, Inc. 3. Cholkar K, Gilger BC, Mitra AK. Topical, aqueous, clear cyclosporine formulation design for anterior and posterior ocular delivery. Transl Vis Sci Technol. 2015;4(3):1-16. 4. Mandal A, Bisht R, Rupenthal ID, Mitra A. Polymeric micelles for ocular drug delivery: from structural frameworks to recent preclinical studies. J Control Release. 2017;248:96-116. 5. Cholkar K, Patel A, Vadlapudi AD, Mitra AK. Novel nanomicellar formulation approaches for anterior and posterior segment ocular drug delivery. Recent Pat Nanomed. 2012;2(2):82-95. 6. CEQUA [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2022.
CEQUA® (cyclosporine ophthalmic solution) 0.09% is a calcineurin inhibitor immunosuppressant indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).
WARNINGS AND PRECAUTIONS
Potential for Eye Injury and Contamination: To avoid the potential for eye injury and contamination, advise patients not to touch the vial tip to the eye or other surfaces.
Use with Contact Lenses: CEQUA should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of CEQUA ophthalmic solution.
The most common adverse reactions reported in greater than 5% of patients were pain on instillation of drops (22%) and conjunctival hyperemia (6%). Other adverse reactions reported in 1% to 5% of patients were blepharitis, eye irritation, headache, and urinary tract infection.
Please see the Full Prescribing Information.